CSS LLC’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.03M Sell
1,892
-865
-31% -$487K 0.04% 341
2026
Q1
$1.63M Buy
2,757
+160
+6% +$79.7K 0.08% 197
2025
Q4
$1.27M Sell
2,597
-550
-17% -$256K 0.06% 258
2025
Q3
$1.32M Sell
3,147
-510
-14% -$172K 0.06% 249
2025
Q2
$1.05M Sell
3,657
-320
-8% -$95.6K 0.05% 320
2025
Q1
$1.23M Buy
3,977
+1,650
+71% +$565K 0.07% 227
2024
Q4
$821K Buy
2,327
+280
+14% +$103K 0.04% 401
2024
Q3
$734K Buy
2,047
+300
+17% +$101K 0.03% 380
2024
Q2
$557K Sell
1,747
-503
-22% -$133K 0.03% 454
2024
Q1
$517K Sell
2,250
-300
-12% -$67.7K 0.03% 436
2023
Q4
$561K Buy
2,550
+100
+4% +$23K 0.03% 377
2023
Q3
$553K Sell
2,450
-350
-13% -$80.6K 0.04% 356
2023
Q2
$618K Buy
2,800
+300
+12% +$66.5K 0.04% 342
2023
Q1
$560K Buy
2,500
+700
+39% +$173K 0.04% 294
2022
Q4
$501K Sell
1,800
-100
-5% -$25.2K 0.03% 381
2022
Q3
$398K Sell
1,900
-400
-17% -$89.4K 0.02% 583
2022
Q2
$542K Buy
2,300
+300
+15% +$61K 0.02% 551
2022
Q1
$359K Buy
+2,000
New +$381K 0.01% 696

Other funds holding UTHR

CSS LLC's UTHR Position: Q2 2026 in Review

CSS LLC reduced its United Therapeutics (UTHR) stake by 31% in Q2 2026, selling an estimated $487K and leaving 1,892 shares worth $1.03M. The position accounts for 0.04% of the portfolio, ranked #341.

CSS LLC first reported a position in UTHR in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.63M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • CSS LLC held 1,892 shares of United Therapeutics worth $1.03M as of Q2 2026.
  • CSS LLC sold 865 United Therapeutics shares in Q2 2026, an estimated $487K.
  • United Therapeutics made up 0.04% of CSS LLC's portfolio in Q2 2026, its #341 holding.
  • CSS LLC first reported a position in United Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • CSS LLC's United Therapeutics position peaked at $1.63M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.